Drugs

, Volume 72, Issue 16, pp 2167–2175

Linaclotide

First Global Approval
  • Vanessa McWilliams
  • Glenn Whiteside
  • Kate McKeage
R&D Insight Profile

Abstract

Linaclotide is a once-daily, orally administered, first-in-class agonist of guanylate cyclase-C that is minimally absorbed. It is being developed to treat gastrointestinal disorders by Ironwood Pharmaceuticals and its partners, Forest Laboratories (North America), Almirall (Europe) and Astellas Pharma (Asia-Pacific). Linaclotide has received its first global approval in the US for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic idiopathic constipation (CIC), and a marketing submission has been filed in the EU for IBS-C. This article summarizes the milestones in the development of linaclotide leading to this first approval for IBS-C and CIC.

References

  1. 1.
    Camilleri M. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome. Clin Pharmacol Ther 2012 January; 91(1): 44–59CrossRefPubMedGoogle Scholar
  2. 2.
    Emmanuel A. Current management strategies and therapeutic targets in chronic constipation. Therap Adv Gastroenterol 2011 Jan; 4(1): 37–48CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Wensel TM, Luthin DR. Linaclotide: a novel approach to the treatment of irritable bowel syndrome. Ann Pharmacother 2011 Dec; 45(12): 1535–43CrossRefPubMedGoogle Scholar
  4. 4.
    Ironwood Pharmaceuticals I. Ironwood and Forest announce FDA approval of LINZESSTM (linaclotide) for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. Media Release. 30 Aug 2012Google Scholar
  5. 5.
    US Food and Drug Administration. FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation [online]. Available from URL: www.fda.gov [Accessed 2010 Aug 30
  6. 6.
    Bionomics L. BNC210 partner Ironwood Pharmaceuticals receives US FDA approval for LINZESS(Tm). Media Release. 31 Aug 2012Google Scholar
  7. 7.
    Ironwood Pharmaceuticals I. Ironwood and Forest announce submission of new drug application for linaclotide for the treatment of irritable bowel syndrome with constipation and chronic constipation. Media Release. 10 Aug 2011Google Scholar
  8. 8.
    Ironwood Pharmaceuticals I, Forest Laboratories I. Ironwood and Forest announce FDA has extended the review period for linaclotide to September 2012. Media Release. 23 Apr 2012Google Scholar
  9. 9.
    Prescribing information: LINZESS (linaclotide) capsules, for oral use [online]. Available from URL: www.frx.com/pi/linzess_pi.pdf
  10. 10.
    Forest Laboratories I. Forest Laboratories, Inc. reports fiscal year first quarter 2013 earnings per share of $0.21 [media release]. 2012 Jul 17 [online]. Available from URL: http://news.frx.com
  11. 11.
    Almirall SA. Almirall announces regulatory filing of linaclotide for the treatment of irritable bowel syndrome with constipation in Europe. Media Release. 29 Sep 2011Google Scholar
  12. 12.
    European Medicines Agency. Summary of opinion (initial authorisation): Constella linaclotide [online]. Available from URL: www.ema.europa.eu
  13. 13.
    Almirall SA, Ironwood Pharmaceuticals I. Almirall and Ironwood announce positive results from a phase 3 trial with linaclotide in patients with irritable bowel syndrome with constipation. Media Release. 14 Sep 2010Google Scholar
  14. 14.
    Almirall SA, Ironwood Pharmaceuticals I. Almirall and Ironwood announce positive results from the second phase 3 trial of linaclotide in patients with irritable bowel syndrome with constipation. Media Release. 2 Nov 2010Google Scholar
  15. 15.
    Johnston JM, Schneier HA. Clarification of trial end points presented in a recent review of linaclotide. Expert Rev 2012 Feb; 6(1): 13–4; author reply 5Google Scholar
  16. 16.
    Ironwood Pharmaceuticals I, Forest Laboratories I. Ironwood and Forest announce positive linaclotide results from second phase 3 trial in patients with irritable bowel syndrome with constipation. Media Release. 2 Nov 2010Google Scholar
  17. 17.
    Ironwood Pharmaceuticals I, Forest Laboratories I. Ironwood and Forest announce positive linaclotide results from phase 3 trial in patients with irritable bowel syndrome with constipation. Media Release. 14 Sep 2010Google Scholar
  18. 18.
    Microbia I. Microbia announces name change to Ironwood Pharmaceuticals [media release]. 2008 Apr 7 [online]. Available from URL: www.ironwoodpharma.com
  19. 19.
    Forest Laboratories I, Microbia I. Microbia and Forest Laboratories announce linaclotide co-development and co-marketing collaboration. Media Release. 17 Sep 2007Google Scholar
  20. 20.
    Almirall SA. Almirall signs a pan-European licensing-in agreement with Ironwood for linaclotide, a novel gastrointestinal compound. Media Release. 2009 May 4Google Scholar
  21. 21.
    Ironwood Pharmaceuticals I. Ironwood announces linaclotide European licensing agreement with Almirall. Media Release. 4 May 2009Google Scholar
  22. 22.
    Almirall SA. Almirall announces a US$15 M equity investment in Ironwood Pharmaceuticals for linaclotide. Media Release. 2009 Nov 10Google Scholar
  23. 23.
    Ironwood Pharmaceuticals I. Ironwood Pharmaceuticals provides third quarter 2010 investor update [media release]. 2010 Nov 4 [online]. Available from URL: www.ironwoodpharma.com
  24. 24.
    Almirall SA. Almirall obtains rights for Linaclotide in Mexico. Media Release. 2012 Sep 7Google Scholar
  25. 25.
    Ironwood Pharmaceuticals I, Astellas Pharma I. Ironwood and Astellas announce Japan licensing agreement for linaclotide. Media Release. 10 Nov 2009Google Scholar
  26. 26.
    Ironwood Pharmaceuticals I. Ironwood Pharmaceuticals provides second quarter 2010 investor update [media release]. 2011 Aug 5 [online]. Available from: www.ironwoodpharma.com
  27. 27.
    Kurtz C, Fitch D, Busby RW, et al. Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacodynamics in healthy subjects. Gastroenterology 2006; 130 (Suppl. 2): 26 (plus oral presentation) abstr. 132Google Scholar
  28. 28.
    Currie MG, Kurtz C, Mahajan-Miklos S, et al. Effects of single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects. Am J Gastroenterol 2005; 100 (Suppl.): 328Google Scholar
  29. 29.
    Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010 May 8; 86(19–20): 760–5CrossRefPubMedGoogle Scholar
  30. 30.
    Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010 Dec 15; 649(1–3): 328–35CrossRefPubMedGoogle Scholar
  31. 31.
    Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010 Mar; 22(3): 312–e84CrossRefPubMedGoogle Scholar
  32. 32.
    Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. Epub 2012 Sep 18; doi: 10.1038/ajg.2012.254Google Scholar
  33. 33.
    Lembo A, Fortea J, Diaz C, et al. 26-week efficacy and safety of once-daily oral linaclotide in patients with irritable bowel syndrome with constipation: a European Perspective. 19th United European Gastroenterology Week; 2011; abstr. OP174Google Scholar
  34. 34.
    Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. Epub 2012 Sep 18; doi: 10.1038/ajg.2012.255Google Scholar
  35. 35.
    Quigley E, Lembo AJ, Diaz C, et al. Significant improvements in abdominal pain and bowel symptoms in a phase 3 trial of linaclotide in patients with irritable bowel syndrome with constipation (Ibs-C): a European perspective. 19th United European Gastroenterology Week; 2011: abstr. OP351Google Scholar
  36. 36.
    Rao SS, Chang L, Hao X, et al. Assessing the percent of days linaclotide improved abdominal symptoms and stool frequency in patients with IBS-C: a pooled analysis of two phase 3 trials. Digestive Disease Week 2012; abstr. Tu1380Google Scholar
  37. 37.
    Locke GR, Chey WD, Kurtz CB, et al. Effects of linaclotide treatment on patient-reported ratings of change for symptoms of irritable bowel syndrome with constipation (IBS-C): pooled 12-week findings from two phase 3 trials. Digestive Disease Week 2012; abstr. Tu1068Google Scholar
  38. 38.
    Carson R, Tourkodimitris S, Lewis BE. Effect of Linaclotide on quality of life in adults with irritable bowel syndrome with constipation: pooled results from two randomized, double-blind, placebo-controlled phase 3 trials. Digestive Disease Week 2011; abstr. 223Google Scholar
  39. 39.
    Buono JL, Tourkodimitris S, Sarocco PW, et al. Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation. Digestive Disease Week 2012; abstr. Tu1402Google Scholar
  40. 40.
    Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010 Dec; 139(6): 1877–86.e2CrossRefPubMedGoogle Scholar
  41. 41.
    Johnston J, MacDougall J, Lavins B, et al. Linaclotide significantly improved abdominal pain, constipation and global assessments in adults with irritable bowel syndrome with constipation: results from a large twelve-week, randomized, double-blind, placebo-controlled study. 73rd Annual Scientific Meeting of the American College of Gastroenterology; 2008; abstr. 1179Google Scholar
  42. 42.
    Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007 Sep; 133(3): 761–8CrossRefPubMedGoogle Scholar
  43. 43.
    Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011 Aug 11; 365(6): 527–36CrossRefPubMedGoogle Scholar
  44. 44.
    Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010 Mar; 138(3): 886–95.e1CrossRefPubMedGoogle Scholar
  45. 45.
    Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009 Jan; 104(1): 125–32CrossRefPubMedGoogle Scholar
  46. 46.
    Chey WD, Lembo A, MacDougall JE, et al. Efficacy and safety of once-daily linaclotide administered orally for 26 weeks in patients with IBS-C: results from a randomized, double-blind, placebo-controlled phase 3 trial. Gastroenterology 2011; (1): S135Google Scholar
  47. 47.
    Astellas Pharma I. R&D Pipeline: global development [online]. Available from URL: http://www.astellas.com/en/ir/library/pdf/1q2013_rd_en.pdf [Accessed 2012 Sep 28

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Vanessa McWilliams
    • 1
  • Glenn Whiteside
    • 1
  • Kate McKeage
    • 2
  1. 1.Springer HealthcareAdis R&D InsightAucklandNew Zealand
  2. 2.AdisAucklandNew Zealand
  3. 3.Adis R&D InsightMairangi Bay, North Shore 0754, AucklandNew Zealand

Personalised recommendations